As of May 22
| -0.66 / -1.39%|
The 18 analysts offering 12-month price forecasts for Novozymes A/S have a median target of 47.05, with a high estimate of 59.94 and a low estimate of 39.09. The median estimate represents a +0.67% increase from the last price of 46.74.
The current consensus among 18 polled investment analysts is to Sell stock in Novozymes A/S. This rating has held steady since May, when it was downgraded from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.